This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here Is Why Bargain Hunters Would Love Fast-paced Mover Inotiv, Inc. (NOTV)
by Zacks Equity Research
Inotiv, Inc. (NOTV) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Wall Street Analysts Predict a 168.98% Upside in Inotiv, Inc. (NOTV): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 169% in Inotiv, Inc. (NOTV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inotiv, Inc. (NOTV) delivered earnings and revenue surprises of -112.50% and 13.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 265.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
4D Molecular Therapeutics, Inc. (FDMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 13% and 0.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Inotiv (NOTV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Inotiv (NOTV) stock based on the movements in the options market lately.
Inotiv, Inc. (NOTV) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Inotiv, Inc. (NOTV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Bears are Losing Control Over Inotiv, Inc. (NOTV), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Inotiv, Inc. (NOTV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
The Zacks Analyst Blog Highlights: Inotiv, Sterling Construction Company, Level One Bancorp, Clearfield and Bluegreen Vacations
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Inotiv, Sterling Construction Company, Level One Bancorp, Clearfield and Bluegreen Vacations
Top 5 High-Flying Small-Cap Stocks to Tap Wall Street Rally
by Nalak Das
We have narrowed down our search to five small business operators that have popped more than 20% in the past month. These are NOTV, STRL, LEVL, CLFD and BVH.